Michael T. Redman, Chairman of the Board and CEO of Oncolix, Inc., is Featured in a New Audio Interview at SmallCapVoice.com Print
By GLOBE NEWSWIRE   
Tuesday, 19 September 2017 02:00

AUSTIN, Texas, Sept. 19, 2017 (GLOBE NEWSWIRE)

AUSTIN, Texas, Sept. 19, 2017 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and Oncolix, Inc. (OTCQB:AEPP), a clinical-stage biotechnology company developing Prolanta™ for the treatment of ovarian cancer, today announced that a new audio interview with the Company is now available. The interview can be heard at http://smallcapvoice.com/blog/9-12-17-smallcapvoice-interview-with-oncolix-inc-aepp.

Michael T. Redman called in to SmallCapVoice.com to go over the business model, management, the ongoing Phase I human clinical trial in ovarian cancer patients and the FDA granting Prolanta Orphan Drug status for the treatment of ovarian cancer in this new interview. Recently the Company consummated a private placement of debt securities, resulting in gross proceeds of $2.0 million. Newbridge Securities Corporation, through LifeTech Capital, acted as lead placement agent for the offering and as financial advisor for the merger.

In the interview Mr. Redman stated, “Our management team is quite diverse because we have experience running companies both big and small and both public and private. A major milestone for 2017 is where we are at in our trials. We have already successfully completed the low dose trials and

we are set to begin our mid dose trials. Looking ahead we will be completing a name and

Error. Page cannot be displayed. Please contact your service provider for more details. (30)

ticker symbol change in 2017. We will continue to work with The University Texas MD Anderson Cancer Center to expand our use of Prolanta. In addition, we have a couple of acquisitions in mind to help boost our pipeline. Finally, we are going to strengthen our Board of Directors. I think our shareholders will be very impressed with these additions to our board over the next sixty to ninety days."

Recently, Oncolix, Inc. was also featured at SCN Corporate Connect and

those videos can be found here: Oncolix Company Overview https://youtu.be/Ox6n1HH8v_0 and Recent Announcements https://youtu.be/DjS71WhZPew

A new article about the Company has been issued: http://smallcapvoice.com/blog/oncolix-creates-a-drug-that-could-change-gynecological-cancer-treatment/.

About SmallCapVoice.com
SmallCapVoice.com is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients' financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit http://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/.

About Oncolix
Oncolix is a clinical-stage biotechnology company developing Prolanta for the treatment of ovarian, uterine, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta in its first indication, the treatment of ovarian cancer. This Phase 1 clinical trial began in 2016. Prolanta is a prolactin receptor antagonist (or blocker) that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. In addition to ovarian cancer, there is strong preclinical evidence Prolanta may be effective in breast, prostate and other cancers. In the current Phase 1 dose-escalation safety trial for the treatment of ovarian cancer, to date there have been no observed serious adverse events and no dose-limiting toxicities. The FDA has approved the designation of Prolanta as an Orphan Drug for the treatment of ovarian cancer, which may result in reduced filing fees (currently $2 million), federal tax credits and marketing exclusivity.

About SCN Corporate Connect
SCN Corporate Connect is a New York based financial media content and distribution platform.  We help companies tell and distribute their stories with professionally scripted, HD quality videos shot in our studios at the NASDAQ and NYSE. SCN Corporate Connect distributes those stories to our strong network of Family Offices, domestically and abroad, and across financial news sites such as Insider Monkey, Benzinga, The Street, Yahoo Finance, Harvest and others.  Forbes recently covered SCN Corporate Connect’s extremely successful Family Office and Life Science Symposium at the NASDAQ, with over 100 Family Offices in attendance: http://bit.ly/2mqBc71Forbes

Forward-Looking Statements
This press release above may contain forward‐looking statements about the business, financial condition and prospects of the Company. Forward looking statements can be identified by the use of forward-looking terminology such as “believes,” “projects,” “expects,” “may,” “goal,” “estimates,” “should,” “plans,” “targets,” “intends,” “could,” or “anticipates,” or the negative thereof, or other variations thereon, or comparable terminology, by discussions of strategy or objectives. Forward-looking statements relate to anticipated or expected events, activities, trends or results. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties.

Although the Company believes that the expectations reflected in forward-looking statements are reasonable, there can be no assurances that such expectations will prove to be accurate. Security holders are cautioned that such forward-looking statements involve risks and uncertainties. The forward-looking statements contained in the press release speak only as of the date of the press release, and the Company expressly disclaims any obligation or undertaking to report any updates or revisions to any such statement to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which any such statement is based. Certain factors may cause results to differ materially from those anticipated by some of the statements made in the press release. Investors are urged to consider closely the disclosures in our Forms 10-K, 10-Q, 8-K and other filings with the SEC, which can be electronically accessed from the SEC's website at http://www.sec.gov/.

Corporate contact:

Michael Redman
P: 281-402-3167
E: mredman@oncolixbio.com

Investor contact:

The Ruth Group
Robert Flamm
P: 646-536-7017
E: rflamm@theruthgroup.com

For SmallCapVoice.com

Stuart T. Smith
512-267-2430
info@smallcapvoice.com

Primary Logo




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1